Raymond James Biotech Innovation Symposium: Eupraxia has a novel extended release platform - with data already out and more on the way later this year, Eosinophilic Esophagitis has been a good PoC
Apr 14
1 min read
CEO James Helliwell describes Euprexia's platform and how it differs from other extended release technologies. Plus, Eosinophilic Esophagitis, and how the company thinks about other uses.
Coverage brought to you by
.png){kind=logo}